Glucocorticoid Receptor 

 186 Products   186 Products   1696 Diseases   95004 News 


«12...369370371372373374375376377378379...10671068»
  • ||||||||||  budesonide / Generic mfg.
    Clinical, Journal:  Major Difference in Particle Size, Minor Difference in Release Profile: A Case Study of Solid Lipid Nanoparticles. (Pubmed Central) -  Feb 12, 2022   
    SLN were synthesized via the hot high-pressure homogenization (HPH) method, budesonide (BUD) was used as the model drug, and BUD-SLN1-BUD-SLN4 with increasing particle size was obtained, i.e. 120, 240, 360, and 480 nm...Noticeably, the release behavior of SLN was to some extent related to the average particle size of SLN, but the correlation was insignificant when the intersection degree of particle size distribution was great. This study provides a new idea for the understanding of in vitro release of SLN, and has a certain referencing value for the research and development of novel nanomedicines.
  • ||||||||||  dexamethasone injection / Generic mfg.
    Journal:  Investigating the growth performance, meat quality, immune function and proteomic profiles of plasmal exosomes in Lactobacillus plantarum-treated broilers with immunological stress. (Pubmed Central) -  Feb 12, 2022   
    In this study, 300 broilers were allocated to three treatments: control diet (CON group), control diet + dexamethasone injection (DEX group), and control diet containing 1 × 10 cfu g P8 + DEX injection (P8 + DEX group)...MRM further revealed that the upregulated FABP6 and EPCAM in the DEX group were decreased by P8 + DEX treatment, and the downregulated C1QTNF3 in the DEX group was increased by P8 + DEX treatment. In conclusion, our findings demonstrated that P8 may promote the immune function, growth performance and meat quality of broilers with immunological stress by regulating the plasma exosomal proteins, especially the proteins of FABP6, EPCAM and C1QTNF3 and the pathway of PPAR (ILK/FABP6).
  • ||||||||||  dexamethasone / Generic mfg.
    Preclinical, Journal:  A ferret model of immunosuppression induced with dexamethasone. (Pubmed Central) -  Feb 12, 2022   
    The dexamethasone treatment proved to be useful for short-term immunosuppression in ferrets. The results closely resembled data previously reported in human studies and indicate classification of ferrets as steroid-resistant species.
  • ||||||||||  dexamethasone / Generic mfg.
    Journal:  Characterizing the metabolic profile of dexamethasone treated human trabecular meshwork cells. (Pubmed Central) -  Feb 12, 2022   
    We found that Dex-treated TM cells had quantifiably altered metabolic profiles, including increased spare respiratory capacity and ATP production rate from oxidative phosphorylation. Therefore, we propose that reversing or preventing these metabolic changes may represent an avenue for future research.
  • ||||||||||  dexamethasone / Generic mfg.
    Preclinical, Journal:  An ex vivo model of human corneal rim perfusion organ culture. (Pubmed Central) -  Feb 12, 2022   
    Also, the stiffness of TM of corneal rims perfused with dexamethasone was significantly higher than the control...Histology studies showed that the TM tissues perfused with plain medium appeared normal. We believed that our glued-based method is a useful tool and low-cost alternative to the traditional anterior segment perfusion culture model.
  • ||||||||||  Actemra IV (tocilizumab) / Roche, JW Pharma
    Review, Journal:  Dabigatran in patients with atrial fibrillation after COVID-19 hospitalization: an update of the ANIBAL protocol. (Pubmed Central) -  Feb 12, 2022   
    Considering the new information, the protocol, named ANIBAL II, has been updated. In this new protocol, the anticoagulant of choice in patients with AF after COVID-19 hospitalization is provided according to three scenarios: with/without dexamethasone treatment at discharge and normal hepatic function, transaminases ≤2 times the upper limit of normal, or transaminases >2 times the upper limit of normal.
  • ||||||||||  dexamethasone / Generic mfg.
    Journal:  Intratympanic Steroid for the Management of Sudden Hearing Loss: Introduction of a Tapering Method. (Pubmed Central) -  Feb 12, 2022   
    This study aimed to present the results of a novel treatment algorithm, which is a combination of systemic steroids and a tapering intratympanic (IT) dexamethasone regimen...The dose, interval, and duration of IT steroid treatment were not universally approved. The treatment method designed based on a tapering of IT steroid injection in combination with already known systemic administration of steroids can be a treatment option in SSNHL patients.
  • ||||||||||  Actemra IV (tocilizumab) / Roche, JW Pharma
    Review, Journal:  Mucormycosis in COVID-19: A systematic review of literature. (Pubmed Central) -  Feb 12, 2022   
    Ten patients (11.5%) had received tocilizumab...Indiscriminate use of steroids in patients needs to be avoided and focus needs to be put on tight blood sugar control in diabetic patients. Studies are needed to confirm the role of the SARS-CoV-2 virus in causing immune dysfunction and mucormycosis.
  • ||||||||||  dexamethasone / Generic mfg.
    Clinical, Journal:  Real-Life Management of Central and Branch Retinal Vein Occlusion: A Seven-Year Follow-Up Study. (Pubmed Central) -  Feb 11, 2022   
    Both CRVO and BRVO eyes experience a significant visual acuity improvement secondary to anti-vascular endothelial growth factor/dexamethasone treatments (from 0.57 ± 0.25 to 0.41 ± 0.24 LogMAR in CRVO and from 0.53 ± 0.42 to 0.30 ± 0.41 LogMAR in BRVO, respectively) (p < 0.01)...After these two time points, both visual acuity and CMT resulted stable up to the end of the follow-up. Ischemia was associated with significantly worse outcome.
  • ||||||||||  dexamethasone / Generic mfg.
    Preclinical, Journal, IO biomarker:  Acanthopanax senticosus total flavonoids alleviate lipopolysaccharide-induced intestinal inflammation and modulate the gut microbiota in mice. (Pubmed Central) -  Feb 11, 2022   
    The experimental mice were divided into a control group, model group (10 mg/kg LPS), dexamethasone group (1 mg/kg DEX) and ASTF low-, medium- and high-dosage groups (200, 400 and 800 mg/kg, respectively)...The TLR4, MyD88 and p-p65/p-65 protein expression levels were also significantly reduced. In addition, 16S rRNA sequencing results show that LPS disrupts the structure of mouse gut microbes, though we ob-served that normal microbial status can be restored through ASTF intervention.
  • ||||||||||  dexamethasone / Generic mfg., lenalidomide / Generic mfg.
    Biomarker, Review, Journal:  Diagnosis and Management of Multiple Myeloma: A Review. (Pubmed Central) -  Feb 11, 2022   
    Approximately 34 920 people in the US and 155 688 people worldwide are diagnosed with multiple myeloma each year. Induction therapy with an injectable proteasome inhibitor, an oral immunomodulatory agent and dexamethasone followed by treatment with autologous hematopoietic stem cell transplantation, and maintenance therapy with lenalidomide are among the treatments considered standard care for eligible patients.
  • ||||||||||  Decadron (dexamethasone) / Merck (MSD)
    Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date:  MUA to Treat Postoperative Stiffness After Total Knee Arthroplasty (clinicaltrials.gov) -  Feb 11, 2022   
    P=N/A,  N=130, Active, not recruiting, 
    Phase classification: P1/2 --> P1 Recruiting --> Active, not recruiting | N=24 --> 130 | Trial completion date: Feb 2024 --> Nov 2022 | Trial primary completion date: Feb 2024 --> Nov 2022
  • ||||||||||  Cingal (hyaluronic acid/triamcinolone) / Anika Therap
    Trial completion, Trial completion date, Trial primary completion date:  Study of Cingal (clinicaltrials.gov) -  Feb 11, 2022   
    P3,  N=25, Completed, 
    Recruiting --> Active, not recruiting | N=24 --> 130 | Trial completion date: Feb 2024 --> Nov 2022 | Trial primary completion date: Feb 2024 --> Nov 2022 Recruiting --> Completed | Trial completion date: Feb 2022 --> Sep 2021 | Trial primary completion date: Feb 2022 --> Sep 2021
  • ||||||||||  Cingal (hyaluronic acid/triamcinolone) / Anika Therap
    Trial completion, Trial completion date, Trial primary completion date:  Study of Cingal (clinicaltrials.gov) -  Feb 11, 2022   
    P3,  N=25, Completed, 
    Recruiting --> Completed | Trial completion date: Feb 2022 --> Sep 2021 | Trial primary completion date: Feb 2022 --> Sep 2021 Recruiting --> Completed | Trial completion date: Feb 2022 --> Sep 2021 | Trial primary completion date: Feb 2022 --> Sep 2021
  • ||||||||||  Cingal (hyaluronic acid/triamcinolone) / Anika Therap
    Trial completion, Trial completion date, Trial primary completion date:  Study of Cingal (clinicaltrials.gov) -  Feb 11, 2022   
    P3,  N=25, Completed, 
    Recruiting --> Completed | Trial completion date: Feb 2022 --> Sep 2021 | Trial primary completion date: Feb 2022 --> Sep 2021 Recruiting --> Completed | Trial completion date: Feb 2022 --> Sep 2021 | Trial primary completion date: Feb 2022 --> Sep 2021
  • ||||||||||  dexamethasone / Generic mfg., melphalan / Generic mfg., lenalidomide / Generic mfg.
    Trial completion date, Trial primary completion date:  DSM XIII: Combination of Lenalidomide and Dexamethasone in Treatment of Multiple Myeloma (clinicaltrials.gov) -  Feb 11, 2022   
    P3,  N=348, Active, not recruiting, 
    Recruiting --> Completed | Trial completion date: Feb 2022 --> Sep 2021 | Trial primary completion date: Feb 2022 --> Sep 2021 Trial completion date: Oct 2021 --> Oct 2022 | Trial primary completion date: Jun 2021 --> Jun 2022
  • ||||||||||  dexamethasone / Generic mfg., cladribine / Generic mfg.
    Clinical, Journal:  Second-line regimen for CNS-involved pediatric Langerhans cell histiocytosis. (Pubmed Central) -  Feb 10, 2022   
    Modification of steroid dosing strategy as well as steroid type may further optimize therapeutic effect of the COVID-19 treatment. A combined therapy with Ara-c, 2-cdA, dexamethasone, and vindesine could partially alleviate pituitary disease conditions in pediatric LCH with CNS involvement, with good tolerance.